Top

Published in:

Open Access 01-12-2013 | Research article

Epistatic study reveals two genetic interactions in blood pressure regulation

Authors: Ndeye Coumba Ndiaye, El Shamieh Said, Maria G Stathopoulou, Gérard Siest, Michael Y Tsai, Sophie Visvikis-Siest

Published in: BMC Medical Genetics | Issue 1/2013

Abstract

Background

Although numerous candidate gene and genome-wide association studies have been performed on blood pressure, a small number of regulating genetic variants having a limited effect have been identified. This phenomenon can partially be explained by possible gene-gene/epistasis interactions that were little investigated so far.

Methods

We performed a pre-planned two-phase investigation: in phase 1, one hundred single nucleotide polymorphisms (SNPs) in 65 candidate genes were genotyped in 1,912 French unrelated adults in order to study their two-locus combined effects on blood pressure (BP) levels. In phase 2, the significant epistatic interactions observed in phase 1 were tested in an independent population gathering 1,755 unrelated European adults.

Results

Among the 9 genetic variants significantly associated with systolic and diastolic BP in phase 1, some may act through altering the corresponding protein levels: SNPs rs5742910 (P_adjusted≤0.03) and rs6046 (P_adjusted =0.044) in F7 and rs1800469 (P_adjusted ≤0.036) in TGFB1; whereas some may be functional through altering the corresponding protein structure: rs1800590 (P_adjusted =0.028, SE=0.088) in LPL and rs2228570 (P_adjusted ≤9.48×10^-4) in VDR. The two epistatic interactions found for systolic and diastolic BP in the discovery phase: VCAM1 (rs1041163) * APOB (rs1367117), and SCGB1A1 (rs3741240) * LPL (rs1800590), were tested in the replication population and we observed significant interactions on DBP. In silico analyses yielded putative functional properties of the SNPs involved in these epistatic interactions trough the alteration of corresponding protein structures.

Conclusions

These findings support the hypothesis that different pathways and then different genes may act synergistically in order to modify BP. This could highlight novel pathophysiologic mechanisms underlying hypertension.

Available only for authorised users

Hua H, Zhou S, Liu Y, Wang Z, Wan C, Li H, Chen C, Li G, Zeng C, Chen L, et al: Relationship between the regulatory region polymorphism of human tissue kallikrein gene and essential hypertension. J Hum Hypertens. 2005, 19 (9): 715-721. 10.1038/sj.jhh.1001875.CrossRefPubMed

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet. 2005, 365 (9455): 217-223.CrossRefPubMed

Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H, Cupples LA, Myers RH: Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension. 2000, 36 (4): 477-483. 10.1161/01.HYP.36.4.477.CrossRefPubMed

Lifton RP, Gharavi AG, Geller DS: Molecular mechanisms of human hypertension. Cell. 2001, 104 (4): 545-556. 10.1016/S0092-8674(01)00241-0.CrossRefPubMed

Pickering GW, Wright AD, Heptinstall RH: The reversibility of malignant hypertension. Lancet. 1952, 2 (6742): 952-956.CrossRefPubMed

Chae CU, Lee RT, Rifai N, Ridker PM: Blood pressure and inflammation in apparently healthy men. Hypertension. 2001, 38 (3): 399-403. 10.1161/01.HYP.38.3.399.CrossRefPubMed

Sass C, Blanquart C, Morange PE, Pfister M, Visvikis-Siest S: Association between factor VII polymorphisms and blood pressure: the Stanislas Cohort. Hypertension. 2004, 44 (5): 674-680. 10.1161/01.HYP.0000144799.41945.a5.CrossRefPubMed

Savoia C, Volpe M, Alonzo A, Rossi C, Rubattu S: Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clin Sci (Lond). 2009, 118 (4): 231-240. 10.1042/CS20090204.CrossRef

Androulakis ES, Tousoulis D, Papageorgiou N, Tsioufis C, Kallikazaros I, Stefanadis C: Essential hypertension: is there a role for inflammatory mechanisms?. Cardiol Rev. 2009, 17 (5): 216-221. 10.1097/CRD.0b013e3181b18e03.CrossRefPubMed

10.

Sicker T, Wuchold F, Kaiser B, Glusa E: Systemic vascular effects of thrombin and thrombin receptor activating peptide in rats. Thromb Res. 2001, 101 (6): 467-475. 10.1016/S0049-3848(00)00429-1.CrossRefPubMed

11.

Niu W, Qi Y, Qian Y, Gao P, Zhu D: The relationship between apolipoprotein E epsilon2/epsilon3/epsilon4 polymorphisms and hypertension: a meta-analysis of six studies comprising 1812 cases and 1762 controls. Hypertens Res. 2009, 32 (12): 1060-1066. 10.1038/hr.2009.164.CrossRefPubMed

12.

Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, et al: Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011, 478 (7367): 103-109. 10.1038/nature10405.CrossRefPubMed

13.

Harrap SB: Blood pressure genetics: time to focus. J Am Soc Hypertens. 2009, 3 (4): 231-237. 10.1016/j.jash.2009.06.001.CrossRefPubMed

14.

Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T, et al: Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009, 41: 677-687. 10.1038/ng.384.CrossRefPubMedPubMedCentral

15.

Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH, Heath SC, Eyheramendy S, et al: Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009, 41: 666-676. 10.1038/ng.361.CrossRefPubMedPubMedCentral

16.

Ding K, Kullo IJ: Genome-wide association studies for atherosclerotic vascular disease and its risk factors. Circ Cardiovasc Genet. 2009, 2 (1): 63-72. 10.1161/CIRCGENETICS.108.816751.CrossRefPubMedPubMedCentral

17.

Thomas D: Gene-environment-wide association studies: emerging approaches. Nat Rev Genet. 2010, 11 (4): 259-272. 10.1038/nrg2764.CrossRefPubMedPubMedCentral

18.

Misono M, Maeda S, Iemitsu M, Nakata Y, Otsuki T, Sugawara J, Zempo H, Yoshizawa M, Miyaki A, Kuno S, et al: Combination of polymorphisms in the beta2-adrenergic receptor and nitric oxide synthase 3 genes increases the risk for hypertension. J Hypertens. 2009, 27 (7): 1377-1383. 10.1097/HJH.0b013e32832b7ead.CrossRefPubMed

19.

Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A, Kafatos A, Martins MC, Sans S, Sass C, et al: Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis. 2000, 152 (2): 475-488. 10.1016/S0021-9150(99)00501-8.CrossRefPubMed

20.

Dasberg H, Blondheim SH, Sadovsky E: An adjustable blood pressure cuff to correct errors due to variations in arm circumference. Br Heart J. 1962, 24: 214-220. 10.1136/hrt.24.2.214.CrossRefPubMedPubMedCentral

21.

Visvikis-Siest S, Siest G: The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases. Clin Chem Lab Med. 2008, 46 (6): 733-747.CrossRefPubMed

22.

Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, Chen JJ, Pullinger CR, Malloy MJ, Siest G, et al: A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res. 1999, 9 (10): 936-949. 10.1101/gr.9.10.936.CrossRefPubMedPubMedCentral

23.

Sass C, Zannad F, Herbeth B, Salah D, Chapet O, Siest G, Visvikis S: Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis. 1998, 140 (1): 89-95. 10.1016/S0021-9150(98)00120-8.CrossRefPubMed

24.

Zee RY, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Ridker PM: Polymorphism in the beta2-adrenergic receptor and lipoprotein lipase genes as risk determinants for idiopathic venous thromboembolism: a multilocus, population-based, prospective genetic analysis. Circulation. 2006, 113 (18): 2193-2200. 10.1161/CIRCULATIONAHA.106.615401.CrossRefPubMed

25.

Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002, 30 (17): 3894-3900. 10.1093/nar/gkf493.CrossRefPubMedPubMedCentral

26.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007, 81 (3): 559-575. 10.1086/519795.CrossRefPubMedPubMedCentral

27.

VanderWeele TJ: Epistatic interactions. Stat Appl Genet Mol Biol. 2010, 9 (1): Article 1-PubMed

28.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama. 2003, 289 (19): 2560-2572. 10.1001/jama.289.19.2560.CrossRefPubMed

29.

Gong M, Hubner N: Molecular genetics of human hypertension. Clin Sci (Lond). 2006, 110 (3): 315-326. 10.1042/CS20050208.CrossRef

30.

Silverman ES, Palmer LJ, Subramaniam V, Hallock A, Mathew S, Vallone J, Faffe DS, Shikanai T, Raby BA, Weiss ST, et al: Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. Am J Respir Crit Care Med. 2004, 169 (2): 214-219.CrossRefPubMed

31.

Salam MT, Gauderman WJ, McConnell R, Lin PC, Gilliland FD: Transforming growth factor- 1 C-509T polymorphism, oxidant stress, and early-onset childhood asthma. Am J Respir Crit Care Med. 2007, 176 (12): 1192-1199. 10.1164/rccm.200704-561OC.CrossRefPubMedPubMedCentral

32.

Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, Feldman DS, Schmittgen TD, Elton TS: The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem. 2007, 282 (33): 24262-24269. 10.1074/jbc.M701050200.CrossRefPubMedPubMedCentral

33.

Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, Hatzigeorgiou AG, Antonarakis SE: Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet. 2007, 81 (2): 405-413. 10.1086/519979.CrossRefPubMedPubMedCentral

34.

Mailly F, Fisher RM, Nicaud V, Luong LA, Evans AE, Marques-Vidal P, Luc G, Arveiler D, Bard JM, Poirier O, et al: Association between the LPL-D9N mutation in the lipoprotein lipase gene and plasma lipid traits in myocardial infarction survivors from the ECTIM Study. Atherosclerosis. 1996, 122 (1): 21-28. 10.1016/0021-9150(95)05736-6.CrossRefPubMed

35.

Mailly F, Tugrul Y, Reymer PW, Bruin T, Seed M, Groenemeyer BF, Asplund-Carlson A, Vallance D, Winder AF, Miller GJ, et al: A common variant in the gene for lipoprotein lipase (Asp9–>Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol. 1995, 15 (4): 468-478. 10.1161/01.ATV.15.4.468.CrossRefPubMed

36.

Chowdhury B, Mantile-Selvaggi G, Miele L, Cordella-Miele E, Zhang Z, Mukherjee AB: Lys 43 and Asp 46 in alpha-helix 3 of uteroglobin are essential for its phospholipase A2 inhibitory activity. Biochem Biophys Res Commun. 2002, 295 (4): 877-883. 10.1016/S0006-291X(02)00767-2.CrossRefPubMed

37.

Tietge UJ, Maugeais C, Lund-Katz S, Grass D, deBeer FC, Rader DJ: Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol. 2002, 22 (7): 1213-1218. 10.1161/01.ATV.0000023228.90866.29.CrossRefPubMed

38.

Hubel CA, Lyall F, Weissfeld L, Gandley RE, Roberts JM: Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. Metabolism. 1998, 47 (10): 1281-1288. 10.1016/S0026-0495(98)90337-7.CrossRefPubMed

39.

Kohara K, Tabara Y, Nakura J, Imai Y, Ohkubo T, Hata A, Soma M, Nakayama T, Umemura S, Hirawa N, et al: Identification of hypertension-susceptibility genes and pathways by a systemic multiple candidate gene approach: the millennium genome project for hypertension. Hypertens Res. 2008, 31 (2): 203-212. 10.1291/hypres.31.203.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/14/2/prepub

Title: Epistatic study reveals two genetic interactions in blood pressure regulation
Authors: Ndeye Coumba Ndiaye
El Shamieh Said
Maria G Stathopoulou
Gérard Siest
Michael Y Tsai
Sophie Visvikis-Siest
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: BMC Medical Genetics / Issue 1/2013
Electronic ISSN: 1471-2350
DOI: https://doi.org/10.1186/1471-2350-14-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Epistatic study reveals two genetic interactions in blood pressure regulation

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Combinational analysis of linkage and exome sequencing identifies the causative mutation in a Chinese family with congenital cataract

Association between mutation of the NF2gene and monosomy 22 in menopausal women with sporadic meningiomas

BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families

Relationship between polymorphisms in vitamin D metabolism-related genes and the risk of rickets in Han Chinese children

Association between UCP2A55V polymorphism and risk of cardiovascular events in patients with multi-vessel coronary arterial disease

Novel PTRF mutation in a child with mild myopathy and very mild congenital lipodystrophy